SURPASS-PEDS: Tirzepatide Improved HbA1c in Youth-Onset Type 2 Diabetes
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
Oral Agents Did Not Match Insulin for Gestational Diabetes Outcomes
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
Dapagliflozin Plus Calorie Restriction Increased Type 2 Diabetes Remission in Early Disease
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
Automated Insulin Delivery Improved HbA1c and Time in Range in Type 2 Diabetes
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.
CONFIDENCE: Finerenone Plus Empagliflozin Reduced Albuminuria More Than Either Drug Alone
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
REDEFINE 2: CagriSema Reduced Weight and HbA1c in Type 2 Diabetes
In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL)
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
Does the Diabetes Conversation Map Improve Knowledge and Self-Management in Type 2 Diabetes?
A single-centre Egyptian RCT found the Diabetes Conversation Map programme improved diabetes knowledge, self-management, and self-efficacy questionnaire scores versus standard education (p < 0.001), with no clinical endpoints reported. PICO summary and expert commentary.
Intensive Below-120 mmHg SBP Control in Diabetes With Prior Stroke: ACCORD-BP Post-Hoc Analysis
A post-hoc ACCORD-BP analysis of 307 patients with type 2 diabetes and prior stroke links intensive SBP control below 120 mmHg to lower MACE risk. PICO summary and expert commentary.
Do Conventional Risk Factor Changes Explain Exenatide’s Cardiovascular Effects? An EXSCEL Post Hoc Analysis
An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide's cardiovascular effects. PICO summary and expert commentary.